The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has funded an ambitious initiative to overcome one of the most perplexing and frustrating mysteries of cancer treatment — how to prevent drug resistance.

Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center’s research programs.

A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.

Each passing day is precious for Deneen Eastridge, but a decade is a priceless gift. The Dallas resident came to Nashville recently to meet Trina Hughes, the stem cell donor who gave her the gift of life 10 years ago.

Vanderbilt's Andreana Holowatyj, PhD, MSCI, has received the National Cancer Institute’s Method to Extend Research in Time Award to support her ongoing investigation into how early-onset colorectal cancer and its treatments impact reproductive health.

Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.

Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.